ESMO 2017: Licensing and reimbursement discrepancies impact patient access to cancer treatment

Discrepancies between licensing and reimbursement decisions have an impact on patient access to cancer treatment, according to research presented at the ESMO 2017 Congress in Madrid. Conducted on behalf of Bristol-Myers Squibb, the study evaluated...

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2xTiAPP
via IFTTT